Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi
View: Text | PDF
Research Article AIDS/HIV Immunology Infectious disease

T cell responses shape infant SIV reservoirs and postintervention control after AAV9-eCD4-Ig and latency reversal

  • Text
  • PDF
Abstract

Early antiretroviral therapy (ART) limits viral reservoir establishment in infants but also constrains virus-specific immunity required to clear reactivated cells. In the early ART context, we evaluated whether combining adeno-associated virus serotype 9–vectored (AAV9-vectored) eCD4-IgG1 with pharmacological latency reversal using the second mitochondria-derived activator of caspases (SMAC) mimetic AZD5582 could promote reservoir reduction and control in SIV-infected infant macaques. AAV9 delivery achieved sustained eCD4-IgG1 expression, and AZD5582 induced on-ART viremia, but the combination did not reduce intact SIV proviral DNA relative to controls. Partial postintervention control of viremia during analytical treatment interruption (ATI) occurred in 2 of 6 infants receiving AAV9-eCD4-IgG1 plus AZD5582 with restricted reservoir expansion during recrudescence at week 13. Intact reservoir size during ATI correlated inversely with on-ART viremia during AZD5582 treatment. Animals were classified as controllers or non-controllers. Controllers did not show increased eCD4-IgG1 expression nor increased on-ART viremia during AZD5582 treatment but harbored less pre-ART intact SIV DNA in PBMCs than non-controllers. Controllers also exhibited higher frequencies and greater polyfunctionality of virus-specific CD8+ T cells prior to ATI. These findings suggest immune control of reservoir size and post-ART viral dynamics in early-treated infants and that AAV9-eCD4-IgG1 plus AZD5582 increases the likelihood of post-ART viral control.

Authors

Jairo A. Fonseca, Alexis C. King, Kaleaha S. Davis, Daniel O’Hagan, Adrian Khoei, Lucas Alves Britto Da Costa, Camryn Cockerham, Mackenzie Cottrell, Stephanie Ehnert, Jennifer S. Wood, Michael D. Alpert, Matthew R. Gardner, Jeffrey D. Lifson, Maud Mavigner, Mauricio A. Martins, Ann Chahroudi

×

Figure 2

AAV9-mediated eCD4-IgG1 expression and effects on plasma viremia.

Options: View larger image (or click on image) Download as PowerPoint
AAV9-mediated eCD4-IgG1 expression and effects on plasma viremia.
(A) An...
(A) Anti–AAV9-neutralizing antibody screening at birth by HEK293T transduction inhibition (1:10 serum dilution). Each symbol represents an individual animal (n = 60 screened). Animals enrolled in the study (n = 20) are shown in orange and the red dashed line denotes the acceptance threshold (<50% neutralization). (B and C) Longitudinal serum eCD4-IgG1 concentration (B) and anti-drug antibody responses (C) in intervention animals (n = 10) after AAV9-eCD4-IgG1 administration at week 3 after SIV infection. Solid green and black lines indicate the mean eCD4-IgG1 concentration and ADA response, respectively, with shaded areas indicating ± SEM with individual animal trajectories in gray. (D and E) Plasma SIV RNA kinetics on a log10 scale in intervention (D) and control (E) animals (n = 10 per group) from infection through ART-mediated viral suppression. Solid blue and orange lines indicate the mean plasma SIV RNA levels in the intervention and control groups, respectively, with corresponding shaded areas indicating ± SEM. Gray lines represent individual animal trajectories. Gray shading denotes the ART period, and the dotted horizontal line indicates the assay limit of detection (60 copies/mL). The dashed vertical line in D indicates the time of AAV9-eCD4-IgG1 administration. (F) Fold difference in plasma viral load between groups, shown on a log10 ratio scale with axis labels expressed as signed fold change (negative values denote lower viremia in the intervention group; the reference value is ± 1). Open symbols are fold differences of geometric means ± pooled SEM of the log10 difference. Mean serum eCD4-IgG1 concentration (green, ± SEM) is overlaid on the right y axis. (G) Model-estimated plasma viral load trajectories derived from mixed-effect models with natural cubic splines. Lines represent estimated marginal means of log10 plasma viral load for intervention (blue) and control (orange) animals, with shaded areas indicating 95% CIs. Yellow highlighting denotes time intervals in which viral load was significantly lower in the intervention group after FDR correction (P < 0.05).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts